Sujata Narayanan

机构：Pfizer (United States), Huntsman Cancer Institute, Seagen (United States) · ORCID：0000-0001-8175-5680

发表论文 56 篇 · 总被引 2338 次 · h-index 17

代表论文

• Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer (2024 · New England Journal of Medicine · 被引 1064)
• Mevrometostat (PF-06821497) in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with abiraterone acetate: The phase 3, randomized MEVPRO-1 study. (2025 · Journal of Clinical Oncology · 被引 5)
• Mevrometostat (PF-06821497) in combination with enzalutamide for androgen receptor pathway inhibitor (ARPI)-naïve patients with metastatic castration-resistant prostate cancer (mCRPC): The phase 3, randomized MEVPRO-2 trial. (2025 · Journal of Clinical Oncology · 被引 4)
• Exposure–Response and Subgroup Analyses to Support Body Weight–Based Dosing of Brentuximab Vedotin in Children and Young Adults with Newly Diagnosed High-risk Classical Hodgkin Lymphoma (2024 · Clinical Cancer Research · 被引 4)
• MEVROMETOSTAT (PF-06821497) IN COMBINATION WITH ENZALUTAMIDE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE: THE PHASE 3, RANDOMIZED MEVPRO-1 STUDY (2025 · Urologic Oncology Seminars and Original Investigations · 被引 3)
• Abstract 6737: Exposure-response and age subgroup analyses to support body-weight (BW) dosing of brentuximab vedotin (BV) in newly diagnosed high-risk classical Hodgkin lymphoma (cHL) in children and young adults (aged 2-21 years [y]): A randomized children’s oncology group phase 3 trial (AHOD1331) (2023 · Cancer Research · 被引 2)